ABSTRACT
Objective:To investigate the occurrence of human papillomavirus (HPV) single and multiple infections in different cervical lesions, and to analyze the distribution of HPV types in patients with single infection and the change of viral load before and after treatment.Methods:A total of 4 783 HPV-DNA-positive cases who were detected by cervical exfoliated cells HPV-DNA testing from May 2017 to March 2019 in Shanxi Provincial People's Hospital were retrospectively analyzed, of which 3 728 cases met the criteria and were included in this study. Fluorescence quantitative polymerase chain reaction (PCR) was used to determine HPV genotype and viral load, and liquid-based thin-layer cytology (TCT) test and colposcopic histopathological diagnosis were performed. According to the histopathological results, the patients were divided into chronic cervicitis+cervical intraepithelial neoplasia (CIN) Ⅰ group, CIN Ⅱ+CIN Ⅲ group and cervical cancer group.Results:A total of 3 364 cases had HPV single infection, of which chronic cervicitis+CIN Ⅰ accounted for 78.27% (2 633/3 364), CIN Ⅱ+CIN Ⅲ accounted for 18.73% (630/3 364), and cervical cancer accounted for 3.00% (101/3 364); 364 cases had HPV multiple infections, of which chronic cervicitis+CIN Ⅰ accounted for 51.65% (188/364), CIN Ⅱ+CIN Ⅲ accounted for 42.58% (155/364), and cervical cancer accounted for 5.77% (21/364). The difference in the proportion of cervical lesions with different pathological grades in HPV single infection and multiple infections was statistically significant ( χ2 = 127.21, P < 0.01). The top four HPV single infection genotypes in chronic cervicitis+CINⅠ group and CINⅡ+CINⅢ group were type 16, 52, 58 and 53, and their proportions were 17.05% (449/2 633), 12.91% (340/2 633), 9.08% (239/2 633) and 8.89% (234/2 633) in chronic cervicitis+CINⅠ group, and 32.22% (203/630), 10.32% (65/630), 8.41% (53/630) and 5.87% (37/630) in CINⅡ+CINⅢ group. In the cervical cancer group, the top two HPV single infection genotypes were type 16 and 18, and their proportions were 81.19% (82/101) and 6.93% (7/101). The viral load of 120 patients with HPV infection was 4.89±1.14 before treatment and 2.86±1.63 after treatment, and the difference was statistically significant ( t = 13.260, P < 0.01). Conclusions:HPV multiple infections are more likely to aggravate the degree of cervical lesions than single infection. Common HPV infection subtypes in different cervical lesions include type 16, 52, 58, 53 and 18.
ABSTRACT
Objective:To explore the application value of urine γ-synuclein (SNCG) in the diagnosis of bladder cancer.Methods:A total of urine samples from 129 patients with bladder cancer (malignant lesion group), 157 patients with urinary system benign lesions (benign lesion group), and 177 healthy people (the healthy control group) from January 2017 to April 2020 in the Fifth Clinical Medical College of Shanxi Medical University and Shanxi Provincial Cancer Hospital were collected. The concentration of SNCG in the collected urine was detected by using enzyme-linked immunosorbent assay. The receiver operating characteristic (ROC) curve was drawn to determine its sensitivity, specificity and accuracy for the diagnosis of bladder cancer.Results:The urine SNCG concentration in malignant lesion group [4.28 ng/ml (0.53-8.79 ng/ml)] was higher than that in healthy controls [1.44 ng/ml (0.56-3.51) ng/ml, H = 122.9, P < 0.01] and benign lesion group [1.97 ng/ml (0.51-5.87) ng/ml, H = 88.2, P < 0.01], and the concentration of urine SNCG in benign lesion group was higher than that in healthy controls ( H = 17.1, P < 0.01). ROC area under the curve (AUC) of urine SNCG in differentiating benign lesion group from healthy controls was 0.871(95% CI 0.819-0.923, P < 0.01), the best cut-off value was 2.79 ng/ml, the diagnostic sensitivity and specificity was 0.798 and 0. 977, respectively. AUC of urine SNCG in differentiating malignant lesion group from benign lesion group was 0.823(95% CI 0.769-0.877, P < 0.01), the best cut-off value was 3.54 ng/ml, the diagnostic sensitivity and specificity was 0.713 and 0.917, respectively. AUC of urine SNCG in differentiating malignant lesion group from healthy controls plus benign lesion group was 0.848 (95% CI 0.797-0.899, P < 0.01), the best cut-off value was 2.87 ng/ml, the diagnostic sensitivity and specificity was 0.791 and 0.901, respectively. Conclusions:The concentration of SNCG in urine of patients with bladder cancer is higher than that of patients with benign urinary lesions and healthy people. Urine SNCG has a good application value in the diagnosis of bladder cancer.